Aarti Drugs Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter
- September 8, 2026
- Posted by: Harsh Piplani
- Category: Results
Aarti Drugs share price Rs 421.50 on 8 September 2026, down 0.35%. Q2 FY27 results date not confirmed. Q1 FY27 net profit Rs 50.13 crore. Q2 FY26 base a profit of Rs 45.16 crore.
Quick Answer
The Aarti Drugs Q2 results date for FY27 is not confirmed, and Aarti Drugs Ltd. had not filed a board meeting intimation with the NSE or BSE as of 8 September 2026. Indian listing rules require the September 2026 quarter results to be published within 45 days of the quarter end, an outer deadline of 14 November 2026. The quarter will be measured against a September 2025 base of Rs 652.88 crore in revenue and a profit of Rs 45.16 crore. This preview uses reported actuals only and carries no estimated revenue or profit figure for the coming quarter.
The Aarti Drugs Q2 results FY27 announcement is the next scheduled earnings event for Aarti Drugs Ltd., a maker of active pharmaceutical ingredients, speciality chemicals and formulations, with anti-biotic and anti-diabetic APIs forming the core of the portfolio. The stock traded at Rs 421.50 on the NSE on 8 September 2026, down 0.35% from the previous close of Rs 423.00, about 21.1% below its 52-week high of Rs 534.55 and 32.2% above its 52-week low of Rs 318.95.
What makes the Aarti Drugs Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 652.88 crore of revenue and a profit of Rs 45.16 crore, while the most recent quarter on record, Q1 FY27, produced Rs 703.59 crore and a profit of Rs 50.13 crore. Everything below is built from those reported figures rather than from any forecast.
Click Here – Get Free Investment Predictions
When Is the Aarti Drugs Q2 Results FY27 Date?
The Aarti Drugs Q2 results date for FY27 is not confirmed. As of 8 September 2026, Aarti Drugs Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.
What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Aarti Drugs Q2 results date becomes public through that filing rather than through any advance announcement.
The Aarti Drugs Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Aarti Drugs.
Aarti Drugs Q2 Results Expectations: What the Market Is Actually Tracking
No verified analyst estimate for the Aarti Drugs Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Aarti Drugs. The Aarti Drugs Q2 results watchlist below is built from what the company has actually reported and disclosed.
The first is API pricing. Aarti Drugs operates in a segment where realisations move with global supply, and the September quarter shows whether the margin improvement to 13.79% in Q1 FY27 from 12.92% a year earlier has held or reversed.
The second is the profit gap. Revenue in Q1 FY27 was Rs 703.59 crore against Rs 590.82 crore a year earlier, yet profit of Rs 50.13 crore was below the Rs 53.97 crore of that base, which means cost inflation has been absorbing the volume gain.
The third is the September 2025 base of Rs 652.88 crore and Rs 45.16 crore. That is a softer profit base than the June quarter faced, so the year-on-year comparison should be more flattering if margins simply hold.
Check Aarti Drugs Ltd. Live Fundamentals on the Univest Screener
Aarti Drugs Q2 Results Preview: The Q1 FY27 Actuals It Builds On
Aarti Drugs Ltd. reported revenue of Rs 703.59 crore in Q1 FY27, up 19.09% from Rs 590.82 crore in Q1 FY26, and a profit of Rs 50.13 crore at the net level, down 7.12% from Rs 53.97 crore in Q1 FY26. These are reported actuals, not estimates.
Sequentially, revenue was down 2.42% over the March 2026 quarter figure of Rs 721.06 crore, and net profit was down 9.28% from Rs 55.26 crore in Q4 FY26. Operating margin stood at 13.79% in Q1 FY27 against 12.92% in the September 2025 quarter, which is the comparison the Aarti Drugs Q2 results print will be read against.
Q2 FY26 Base: The Comparison Aarti Drugs Q2 Results FY27 Must Beat
Aarti Drugs Ltd. reported revenue of Rs 652.88 crore and a profit of Rs 45.16 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Aarti Drugs Q2 results preview.
Net profit in that base quarter was below the Rs 50.13 crore just reported for Q1 FY27, so the year-on-year comparison starts from a manageable level. Revenue of Rs 652.88 crore sits below the Rs 703.59 crore of the June 2026 quarter, which frames how much sequential movement the Aarti Drugs Q2 results print needs to show growth.
Aarti Drugs Quarterly Results Trend Over the Last Four Quarters
| Quarter | Revenue (Rs Cr) | Net Profit (Rs Cr) |
|---|---|---|
| Q2 FY26 (Sep 2025) | 652.88 | 45.16 |
| Q3 FY26 (Dec 2025) | 602.94 | 40.55 |
| Q4 FY26 (Mar 2026) | 721.06 | 55.26 |
| Q1 FY27 (Jun 2026) | 703.59 | 50.13 |
Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company’s exchange filings, and they are the only basis this Aarti Drugs Q2 results preview uses.
Revenue across those four quarters ranged from Rs 602.94 crore to Rs 721.06 crore, and net profit from Rs 40.55 crore to Rs 55.26 crore. That spread is the honest context for the Aarti Drugs Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.
Key Factors That Could Shape Aarti Drugs Q2 Results FY27
The Aarti Drugs Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Aarti Drugs has already reported.
Raw Material Cost and Chinese Supply
Key starting materials for anti-biotic and anti-diabetic APIs are exposed to Chinese supply and pricing. A move in input cost shows up in gross margin within a quarter, which is why the operating margin line is read before the revenue line here.
Regulatory Inspections and Export Mix
API makers depend on plant approvals to serve regulated export markets. Any inspection outcome or facility update disclosed with the results affects the revenue mix for several quarters, not just the one being reported.
Undemanding Valuation Against the Sector
The stock trades at a price-to-earnings ratio of 20.24 against a sector average of 37.70, with a return on equity of 12.58% and a debt-to-equity ratio of 0.37. That discount reflects the margin pressure rather than a lack of scale.
Aarti Drugs Q2 Results FY27: Share Price and Valuation Going Into the Print
Aarti Drugs share price today is Rs 421.50 on the NSE, down Rs 1.50 or 0.35% from the previous close of Rs 423.00 on 8 September 2026, ahead of the Aarti Drugs Q2 results announcement.
| Metric | Value (8 September 2026) |
|---|---|
| NSE Symbol | AARTIDRUGS |
| Current Market Price | Rs 421.50 |
| 52-Week High | Rs 534.55 |
| 52-Week Low | Rs 318.95 |
| Market Capitalisation | Rs 3,868 crore |
| PE Ratio | 20.24 |
| Sector PE | 37.70 |
| PB Ratio | 2.50 |
| EPS (TTM) | Rs 20.94 |
| Book Value per Share | Rs 169.70 |
| Debt to Equity | 0.37 |
| Return on Equity | 12.58% |
| 50-Day Moving Average | Rs 412.37 |
| 200-Day Moving Average | Rs 387.64 |
| RSI (14) | 60.76 |
The stock trades above both its 50-day average of Rs 412.37 and its 200-day average of Rs 387.64, with a 14-day RSI of 60.76. None of this is a view on where the shares go once the Aarti Drugs Q2 results are announced, and no price target is offered here.
Download the Univest iOS App or Univest Android App to track Aarti Drugs Ltd. live price and quarterly earnings updates.
What Investors Should Watch When Aarti Drugs Q2 Results Are Announced
Four lines carry most of the information in a company of this size, and reading them in order keeps the Aarti Drugs Q2 results print in proportion.
- Revenue against the Rs 652.88 crore reported in the September 2025 base quarter
- Net profit against a profit of Rs 45.16 crore in that same quarter
- Operating margin against 13.79% in Q1 FY27
- Any exceptional item, provision or one-off gain disclosed alongside the numbers
A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Aarti Drugs Q2 results announcement should be read together with the notes to the results rather than the headline alone.
Conclusion on Aarti Drugs Q2 Results FY27
The Aarti Drugs Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Aarti Drugs Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.
On that basis the Aarti Drugs Q2 results FY27 print faces a base of Rs 652.88 crore in revenue and a profit of Rs 45.16 crore, with the most recent quarter having delivered Rs 703.59 crore and a profit of Rs 50.13 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Aarti Drugs, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Aarti Drugs Q2 Results FY27
What is the Aarti Drugs Q2 results date for FY27?
Ans. The Aarti Drugs Q2 results date for FY27 is not confirmed. Aarti Drugs Ltd. had not filed a board meeting intimation with the NSE or BSE as of 8 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.
What quarter do the Aarti Drugs Q2 results 2026 cover?
Ans. The Aarti Drugs Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Aarti Drugs Ltd. reports revenue, operating profit and net profit for that period, and the Aarti Drugs Q2 results filing also carries the notes to the accounts.
What were the Aarti Drugs Q1 FY27 results?
Ans. Aarti Drugs Ltd. reported revenue of Rs 703.59 crore in Q1 FY27 and a profit of Rs 50.13 crore at the net level. Revenue was up 19.09% versus Q1 FY26 and net profit was down 7.12% from Rs 53.97 crore in Q1 FY26.
What were Aarti Drugs Q2 FY26 results in the September 2025 quarter?
Ans. Aarti Drugs Ltd. reported revenue of Rs 652.88 crore and a profit of Rs 45.16 crore in Q2 FY26. Operating margin was 12.92%. Those figures form the base for the Aarti Drugs Q2 results FY27 comparison.
What are the main Aarti Drugs Q2 results expectations this quarter?
Ans. No verified analyst estimate is publicly available. The Aarti Drugs Q2 results expectations centre on revenue against the Rs 652.88 crore base, net profit against a profit of Rs 45.16 crore, operating margin against 13.79% in Q1 FY27, and any exceptional item disclosed with the numbers.
What is Aarti Drugs share price today ahead of the Q2 earnings?
Ans. Aarti Drugs share price is Rs 421.50 on the NSE as of 8 September 2026, down 0.35% from Rs 423.00. The stock is about 21.1% below its 52-week high of Rs 534.55 and 32.2% above its 52-week low of Rs 318.95, at a market capitalisation of Rs 3,868 crore.
Is Aarti Drugs a good stock to buy before the Q2 results?
Ans. This article does not offer a buy, sell or hold recommendation on Aarti Drugs Ltd.. The stock trades at a price-to-book ratio of 2.50 with a return on equity of 12.58%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.
